Perth Children's Hospital

The trials here

What the 25 trials at this site are about, from their registry records.

Conditions

• Childhood cancers11 trials
• Duchenne muscular dystrophy3 trials
• Type 1 diabetes3 trials
• Crohn's disease2 trials
• Type 2 diabetes2 trials
• Acute myeloid leukaemia1 trial
• Cytomegalovirus infection1 trial
• Haemophilia1 trial
• Neuroblastoma1 trial
• Obesity1 trial
• Ulcerative colitis1 trial

Phase

• Phase 313 trials
• Phase 29 trials
• Phase 1/22 trials

Status

• Recruiting13 trials
• Active, not recruiting8 trials
• Completed2 trials
• Terminated2 trials

Lead sponsor

• Hoffmann-La Roche4 trials
• Novo Nordisk A/S2 trials
• Pfizer2 trials
• Australian & New Zealand Children's Haematology/Oncology Group1 trial
• Day One Biopharmaceuticals, Inc.1 trial
• and 15 more

Running trials

• Recruiting

  A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

  NCT07298421· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

  NCT07158242· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

  NCT07253285· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

  NCT07187531· Phase 2· SAb Biotherapeutics, Inc.· Source

  Contact: Charly Keough

• Active, not recruiting

  A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

  NCT06413706· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

  NCT06056297· Phase 3· X4 Pharmaceuticals· Source

  Contact: Patient Affairs and Advocacy

• Recruiting

  A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT05923073· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

  NCT05996003· Phase 2· NS Pharma, Inc.· Source

• Recruiting

  A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

  NCT05319353· Phase 3· Takeda· Source

  Contact: Michelle Ng, MD (principal investigator)

• Active, not recruiting

  Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

  NCT05743244· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Active, not recruiting

  Minimising Adverse Drug Reactions and Verifying Economic Legitimacy in Children (MARVEL-PIC)

  NCT05667766· Murdoch Childrens Research Institute· Source

• Active, not recruiting

  DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

  NCT05566795· Phase 3· Day One Biopharmaceuticals, Inc.· Source

• Recruiting

  ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

  NCT05580562· Phase 3· Jazz Pharmaceuticals· Source

  Contact: Santosh Valvi

• Recruiting

  A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

  NCT05533775· Phase 1/2· Hoffmann-La Roche· Source

• Active, not recruiting

  Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  NCT05183035· Phase 3· PedAL BCU, LLC· Source

• Recruiting

  Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

  NCT05465174· Phase 2· Sabine Mueller, MD, PhD· Source

  Contact: Santosh Valvi

• Recruiting

  Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour

  NCT05230758· Phase 3· Donald Mabbott· Source

  Contact: Santosh Valvi, MBBS

• Recruiting

  Combination Therapy for the Treatment of Diffuse Midline Gliomas

  NCT05009992· Phase 2· University of California, San Francisco· Source

  Contact: Santosh Valvi, FRACP, MD, MSc

• Active, not recruiting

  A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

  NCT04431726· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

  NCT04281485· Phase 3· Pfizer· Source

• Recruiting

  INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

  NCT03838042· Phase 1/2· University Hospital Heidelberg· Source

  Contact: Nick Gottardo (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers6 recruiting
• Crohn's disease2 recruiting
• Cytomegalovirus infection1 recruiting
• Obesity1 recruiting
• Type 1 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Insulin and Abatacept in Recently-diagnosed Type 1 Diabetes

  NCT05742243· Phase 2· Melbourne Health· Source

• Terminated

  Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

  NCT05429372· Phase 2· Pfizer· Source

• Completed

  A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

  NCT04596631· Phase 3· Novo Nordisk A/S· Source

• Terminated

  A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

  NCT04897880· Phase 2· Australian & New Zealand Children's Haematology/Oncology Group· Source